ArticleAnnals of surgical oncology2026
Axillary Recurrence and Survival After Omission of Axillary Lymph Node Dissection in Patients with Breast Cancer and Micrometastases or Isolated Tumor Cells in the Sentinel Node: A Danish National Register Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCompletion axillary lymph node dissection (ALND) is no longer routinely recommended for patients with breast cancer and minimal nodal involvement. In 2012, Danish national guidelines were revised to omit ALND for patients with sentinel node (SN) micrometastases (pN1mi) or isolated tumor cells (pN0[i+]). Long-term evidence on axillary recurrence (AR) and overall survival (OS), particularly after mastectomy, remain limited. This nationwide retrospective register-based study evaluated long-term outcomes after omission of ALND.
methodsClinically node-negative women with pN1mi/pN0(i+) diagnosed between 2008 and 2021 were identified in the Danish Breast Cancer Group database. Patients treated before 2012 (ALND group) were compared with those treated after guideline revision in 2012 (no-ALND group). Both groups were compared with node-negative patients (pN0) treated after 2012. The primary endpoint was AR, and the secondary endpoint was OS. Survival was analyzed using Kaplan-Meier and multivariable Cox regression.
resultsAmong 22,253 eligible patients, 5066 had pN1mi/pN0(i+). The median follow-up period was 6.4 years. Axillary recurrence occurred for 1.1% of the patients overall and was more frequent among the patients without ALND than among those with ALND (1.5% vs 0.2%; p < 0.001). Among the pN0 patients without ALND, 0.5% experienced AR. Long-term OS for the pN1mi/pN0(i+) patients was 81.3% (95% confidence interval, 79.9-82.7), with no significant difference after adjustment for prognostic factors (p = 0.6). Mastectomy-specific analysis showed no difference in OS (p = 0.08).
conclusionOmission of ALND for patients with minimal SN involvement was associated with a slightly higher rate of AR but no adverse impact on long-term OS. These findings support continued de-escalation of axillary surgery, even for selected patients undergoing mastectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.